Patents by Inventor Jeffrey Ledbetter
Jeffrey Ledbetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9416188Abstract: Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.Type: GrantFiled: January 12, 2016Date of Patent: August 16, 2016Assignee: University of Washington Through Its Center For CommercializationInventors: Jay Chaplin, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Edward A. Clark
-
Publication number: 20160168257Abstract: Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.Type: ApplicationFiled: January 12, 2016Publication date: June 16, 2016Inventors: Jay Chaplin, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Edward A. Clark
-
Patent number: 9260529Abstract: The present invention provides novel CD180 binding molecules, methods for their identification, and methods for their use.Type: GrantFiled: February 24, 2011Date of Patent: February 16, 2016Assignee: The University of Washington Through Its Center For CommercializationInventors: Martha Hayden-Ledbetter, Jeffrey Ledbetter
-
Publication number: 20120020965Abstract: The present invention provides novel CD180 binding molecules, methods for their identification, and methods for their use.Type: ApplicationFiled: February 24, 2011Publication date: January 26, 2012Applicants: higher educationInventors: Jay Chaplin, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Ed Clark
-
Publication number: 20080031876Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: ApplicationFiled: March 19, 2007Publication date: February 7, 2008Applicant: Bristol-Myers Squibb CompanyInventors: Peter Linsley, Jeffrey Ledbetter, Nitin Damle, William Brady, Philip Wallace
-
Publication number: 20070237779Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgGI hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: December 24, 2003Publication date: October 11, 2007Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter, Peter Thompson
-
Publication number: 20070059306Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: July 25, 2006Publication date: March 15, 2007Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Laura Grosmaire, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Peter Thompson, Sandy Simon, William Brady
-
Publication number: 20070025982Abstract: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.Type: ApplicationFiled: October 3, 2006Publication date: February 1, 2007Applicant: TRUBION PHARMACEUTICALSInventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050261478Abstract: The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.Type: ApplicationFiled: May 12, 2005Publication date: November 24, 2005Applicant: XCYTE Therapies, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden Ledbetter, William Brady, Laura Grosmaire, Che-Leung Law, Raj Dua
-
Publication number: 20050238646Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: October 27, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202012Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202028Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202023Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202534Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202011Abstract: The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.Type: ApplicationFiled: January 4, 2005Publication date: September 15, 2005Inventors: Christian Larsen, Alejandro Aruffo, Diane Hollenbaugh, Peter Linsley, Jeffrey Ledbetter, Thomas Pearson
-
Publication number: 20050186216Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 25, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050180970Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 18, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050175614Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 11, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050169919Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: ApplicationFiled: June 13, 2003Publication date: August 4, 2005Inventors: Peter Linsley, Jeffrey Ledbetter, Nitin Damle, William Brady
-
Publication number: 20050163708Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: ApplicationFiled: September 15, 2004Publication date: July 28, 2005Inventors: Randy Robinson, Alvin Liu, Jeffrey Ledbetter